Lymphoma

A new drug was approved for patients with cutaneous T-cell lymphoma (CTCL).

Calquence (acalabrutinib) was granted an accelerated approval by the FDA to treat adult patients with mantle cell lymphoma (MCL) following at least one prior therapy. The approval was based on objective response rates (ORR) in a single-arm trial.

Cobra, baseball cards and two guys who always let me know I wasn't dead.

Yescarta was granted FDA approval for use in adults with relapsed or refractory non-Hodgkin lymphoma. This is only the second CAR T-cell therapy ever approved.

Adcetris (brentuximab vedotin) was granted a breakthrough therapy designation by the Food and Drug Administration (FDA) for the frontline treatment of patients who have classical Hodgkin lymphoma

Aliqopa (copanlisib) was granted FDA approval for the treatment of patients with relapsed follicular lymphoma who have received at least two least prior systemic therapies.

The Food and Drug Administration (FDA) granted a priority review to a supplemental biologics license application (sBLA) for Gazyva (obinutuzumab) to be used in combination with chemotherapy for first-line treatment of patients who have follicular lymphoma, according to Genentech, the manufacturer of the drug.

A type of CAR-T cell therapy is showing promise in a phase 1 study for patients with Hodgkin lymphoma and ALCL.

To prevent family conflicts over cancer treatment decisions, experts recommend a series of frank conversations.

Acalabrutinib was granted a priority review to a new drug application (NDA) to be used to treat patients with mantle cell lymphoma (MCL) who have had previous treatment, according to AstraZeneca, the manufacturer of the drug.

A recent study found that children of older parents may have an increased risk of certain types of cancers.

Keytruda (pembrolizumab) and Rituxan (rituximab) showed promising results for patients with follicular lymphoma in a recent study.

Patients with mantle cell lymphoma who were treated with Imbruvica had a better quality of life than those treated with another agent, according to the results of a recent study.

A recent study could be practice-changing for the treatment of cutaneous T-cell lymphoma.

ClearLLab multicolor reagents (T1, T2, B1, B2, M) gained approval from the Food and Drug Administration (FDA) to detect chronic leukemia, acute leukemia, non-Hodgkin lymphoma, multiple myeloma, myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN). This is the first approval the agency received for immunophenotyping on a flow cytometer.

Irene Hutchins, M.D., and her patient Steve Valentine, both accomplished ballroom dancers, made a pact to dance together once he had recovered from late-stage Burkitt lymphoma. They performed their victory dance June 11 during Cancer Survivors Day at Scripps Green Hospital, in La Jolla, California, where Hutchins treated Valentine.

Rituxan Hycela (rituximab) was granted approval by the Food and Drug Administration (FDA) for adult patients with previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma (DLBCL) and previously untreated and previously treated chronic lymphocytic leukemia (CLL).

Expert Lisa G. Roth, M.D., discusses the unique needs of AYA patients with Hodgkin lymphoma.

JCAR017 had promising complete response and objective response rates in treating patients with diffuse large B-cell lymphoma (DLBCL) in a recently presented study.

Opdivo had promising response rates in a recent trial testing the treatment in patients with relapsed or refractory Hodgkin lymphoma.

Pairing two drugs that have shown to be effective in treating lymphoma might be the next step for mantle cell lymphoma treatment.

When we are surviving cancer, when we want to see everybody else survive it too, another death is hard to take. When somebody passes, we are reminded of our own mortality—and distant losses—even as we mourn. Poetry helps.

Peter Martin, M.D., discusses the evolving field of mantle cell lymphoma treatment.

Axicabtagene ciloleucel (KTE-C19; axi-cel) was granted a priority review by the Food and Drug Administration (FDA) for the treatment of transplant-ineligible patients with relapsed or refractory non-Hodgkin lymphoma (NHL).